Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jul 22 · below the Ichimoku cloud · RSI 39 · MACD below its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $1.8M | 0.00% | 111.70K | −36% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NPCE trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 17, 2026 | Fischer Frank MDirector | Stock Award(Grant) at price 15.63 per share. | 1.5K | $22.93K |
| Jun 17, 2026 | Geiger UriDirector | Stock Award(Grant) at price 15.63 per share. | 789 | $12.33K |
| Jun 17, 2026 | Kumar RakhiDirector | Stock Award(Grant) at price 15.63 per share. | 989 | $15.46K |
| Jun 4, 2026 | Fischer Frank MDirector | Stock Award(Grant) at price 0.00 per share. | 2.9K | — |
| Jun 4, 2026 | Huennekens R ScottDirector | Stock Award(Grant) at price 0.00 per share. | 2.9K | — |
| Jun 4, 2026 | Geiger UriDirector | Stock Award(Grant) at price 0.00 per share. | 2.9K | — |
| Jun 4, 2026 | Andrade Lisa MaldenDirector | Stock Award(Grant) at price 0.00 per share. | 2.9K | — |
| Jun 4, 2026 | Kumar RakhiDirector | Stock Award(Grant) at price 0.00 per share. | 2.9K | — |
| Jun 4, 2026 | Ryan ReneeDirector | Stock Award(Grant) at price 0.00 per share. | 2.9K | — |
| May 14, 2026 | Williams Patrick FChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 16.8K | — |
| May 14, 2026 | Becker JoelChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 45.9K | — |
| May 14, 2026 | Morrell Martha JOfficer | Stock Award(Grant) at price 0.00 per share. | 5.5K | — |
| Mar 19, 2026 | Lacob Joseph SDirector | Stock Award(Grant) at price 13.00 per share. | 865 | $11.24K |
| Mar 19, 2026 | Fischer Frank MDirector | Stock Award(Grant) at price 13.00 per share. | 1.8K | $23.74K |
| Mar 19, 2026 | Geiger UriDirector | Stock Award(Grant) at price 13.00 per share. | 913 | $11.87K |
| Mar 19, 2026 | Kumar RakhiDirector | Stock Award(Grant) at price 13.00 per share. | 1.2K | $14.99K |
| Dec 18, 2025 | Lacob Joseph SDirector | Stock Award(Grant) at price 16.59 per share. | 678 | $11.25K |
| Dec 18, 2025 | Fischer Frank MDirector | Stock Award(Grant) at price 16.59 per share. | 1.4K | $23.74K |
| Dec 18, 2025 | Geiger UriDirector | Stock Award(Grant) at price 16.59 per share. | 715 | $11.86K |
| Dec 18, 2025 | Kumar RakhiDirector | Stock Award(Grant) at price 16.59 per share. | 904 | $15.00K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.0 | -3.6 | -9.8 | 28.2 | -1.9 | -3.9 | -18.9 | 13.7 | -6.1 | -7.8 | −17.9% | ||
| 2025 | 23.0 | -5.9 | -5.1 | -4.9 | 13.1 | -15.7 | -23.6 | 7.5 | 12.7 | -3.6 | 64.6 | -5.6 | +38.0% |
| 2024 | 41.8 | 10.6 | -18.4 | -1.6 | -46.8 | 9.4 | 2.2 | 2.5 | -12.0 | -7.5 | 64.3 | 5.6 | +8.5% |
| 2023 | 214.1 | 9.6 | -9.6 | 7.8 | -11.0 | 0.9 | -7.6 | 126.3 | 3.6 | -30.6 | 33.2 | 14.7 | +591.9% |
| 2022 | -20.0 | -3.2 | 5.3 | -2.1 | -22.5 | -20.5 | 18.4 | -27.5 | -11.8 | -20.0 | -46.3 | -7.5 | −85.2% |
| 2021 | -5.1 | 3.8 | -10.5 | -0.3 | -25.4 | -4.4 | -34.0 | 0.8 | −58.3% |
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Buy / hold / sell counts